FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga

FDA greenlights second Ebola treatment in three months, handing new OK to Ridgeback's Ebanga

Source: 
Endpoints
snippet: 

A husband-and-wife biotech that flipped a Covid-19 antiviral to Merck earlier this summer has a new approval in another highly infectious disease — Ebola.

Ridgeback Biotherapeutics, run by CEO Wendy Holman and her husband Wayne Holman, a hedge fund manager who used to work for a company involved in one of the biggest insider trading scandals in history, has clinched an FDA OK for ansuvimab-zykl to treat the deadly Ebola virus in adults and children. The drug, a monoclonal antibody, will be marketed as Ebanga.